Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy

Haematologica

Volumn 99, Issue 3, 2014, Pages 474-480

  Delavigne, Karen ^a,d   Bérard, Emilie ^b,c   Bertoli, Sarah ^a   Corre, Jill ^a   Duchayne, Eliane ^a   Demur, Cécile ^a   Mansat De Mas, Véronique ^a,d   Borel, Cécile ^a,d   Picard, Muriel ^a   Alvarez, Muriel ^a   Sarry, Audrey ^a   Huguet, Françoise ^a   Récher, Christian ^a,d  

^a CHU PURPAN   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c Faculté de Médecine Centre Hospitalo universitaire   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; C REACTIVE PROTEIN; CIPROFLOXACIN; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FERRITIN; FIBRINOGEN; FLUDARABINE; GEMTUZUMAB; IDARUBICIN; IMATINIB; IMIPENEM; IMMUNOGLOBULIN; LOMUSTINE; OZOGAMICIN; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; TRIACYLGLYCEROL; VANCOMYCIN; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APLASIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW BIOPSY; CLINICAL FEATURE; CYTOLOGY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMOPHAGOCYTIC SYNDROME; HEPATOMEGALY; HERPES VIRUS INFECTION; HUMAN; IMMUNE RESPONSE; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; MYCOSIS; OVERALL SURVIVAL; PANCYTOPENIA; SPLENOMEGALY; THROMBOCYTE COUNT; BONE MARROW; COMPLICATION; LEUKEMIA, MYELOID, ACUTE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; FEMALE; FERRITINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84895750755     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.097394     Document Type: Article

References (23)

1. Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21(5):245-53.
2. Arico M, Janka G, Fischer A, Henter JI, Blanche S, Elinder G, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996;10(2):197-203.
3. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991;18(1): 29-33.
4. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-31.
5. Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/ macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med. 2009;10(3):387-92.
6. Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr Opin Pediatr. 2012;24(1):9-15.
7. Strauss R, Neureiter D, Westenburger B, Wehler M, Kirchner T, Hahn EG. Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients--a postmortem clinicopathologic analysis. Crit Care Med. 2004;32(6):1316-21.
8. Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118(22):5794-8.
9. Falini B, Pileri S, De Solas I, Martelli MF, Mason DY, Delsol G, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood. 1990;75(2):434-44.
10. Ferreri AJ, Dognini GP, Campo E, Willemze R, Seymour JF, Bairey O, et al. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica. 2007;92(4):486-92.
11. Han AR, Lee HR, Park BB, Hwang IG, Park S, Lee SC, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol. 2007;86(7):493-8.
12. Bertozzi AI, Suc A, Rubie H, Duchayne E, Demur C, Robert A. [Hemophagocytic syndrome associated with neutropenia after chemotherapy]. Arch Pediatr. 2002;9(2):125-9.
13. Bertoli S, Berard E, Huguet F, Huynh A, Tavitian S, Vergez F, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013;121(14):2618-26.
14. LaRochelle O, Bertoli S, Vergez F, Sarry JE, Mansat-De Mas V, Dobbelstein S, et al. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget. 2011;2(11):850-61.
15. Wang S, Degar BA, Zieske A, Shafi NQ, Rose MG. Hemophagocytosis exacerbated by G-CSF/GM-CSF treatment in a patient with myelodysplasia. Am J Hematol. 2004;77(4):391-6.
16. Roth B, Grande PO, Nilsson-Ehle P, Eliasson I. Possible role of short-term parenteral nutrition with fat emulsions for development of haemophagocytosis with multiple organ failure in a patient with traumatic brain injury. Intensive Care Med. 1993; 19(2):111-4.
17. Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol. 2013;161(5):609-22.
18. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-52.
19. Chen RL, Lin KH, Lin DT, Su IJ, Huang LM, Lee PI, et al. Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol. 1995;89(2):282-90.
20. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154-7.
21. Barclay AN, Brown MH. The SIRP family of receptors and immune regulation. Nat Rev Immunol. 2006;6(6):457-64.
22. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286-99.
23. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271-85.